26 October 2016 EMA/825257/2015 Stakeholders and Communication Division
Agenda - EMA Human Scientific Committees' Working Parties with Patients’ and Consumers’ Organisations (PCWP) and Healthcare Professionals’ Organisations (HCPWP) joint meeting Workshop on social media 19 Sep 2016, 08:30hrs to 17:15hrs – meeting room: 2A Chair: I. Moulon (EMA)
Background Social media 1 is a group of electronic communication tools that have the potential to change how healthcare professionals, researchers, patients and consumers manage and share information in the digital age. They may impact on how information on medicines and their use is generated, shared and discussed. However, the role of social media in providing validated data and amplifying the voice of stakeholders in health care requires additional evidence. The PCWP and HCPWP would like to discuss challenges and practical applications of social media and their impact on regulators, healthcare professionals and patients.
Objectives 1. Provide an overview of what social media are and how they are used in relation to health, with a particular focus on medicine-related uses; 2. Share healthcare professionals’, patients’ and regulators’ practices on how social media are used to amplify communication on medicines information and regulatory decisions; 3. Discuss how social media are or could be used for gathering medicine-related data; 4. Reflect on how communication and data gathering through social media may: 4.1.
Influence medicine-related behaviours and attitudes;
4.2.
Impact regulatory decisions;
1
Definition of Social Media (Source: Merriam-Webster's Learner's Dictionary)): forms of electronic communication (as Web sites for social networking and microblogging) through which users create online communities to share information, ideas, personal messages, and other content (as videos) 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact
5. Identify areas requiring further attention from regulators, patients and healthcare professionals.
19 September 2016 08:30
Registration and reimbursement arrangements
08:50
Welcome
I. Moulon (EMA)
Health and safety information Interests disclosure 09:00
Introduction and objectives
M. Carr (EMA)
09:10
Opening remarks
D. Haerry (PCWP)/ G. Calvo (HCPWP)
1. What is social media and what is it used for? 09:20
1.1
Going viral: the state of play and potential of social
M-K. Looi (Wellcome Trust
media in 2016
London)
2. Medicines communication using social media – how do we get it right? Session chair: Marie-Agnes Heine, EMA Head of Communication 10:00
2.1
Findings from the PCWP/HCPWP topic group on Social
D. Singer (EACPT)
media 2.2
EMA: towards increased engagement through social
S. Labbe (EMA)
media
11:30
2.3
The experience from US FDA
C. Chew/K. Chiu (US FDA)
2.4
Virtual interaction with real patients
A. Daturi (Fondazione Telethon)
Coffee
3. Can social media impact medicines use, stakeholders’ interactions and decision making? Session chair: Isabelle Moulon, EMA Head of Public Engagement 11:45
Introduction to the breakout sessions
12:00
3.1
Breakout sessions
Participants will be distributed in smaller groups and asked to discuss one of the following three dimensions: •
Influence on medicine-related behaviours and attitudes;
•
Impact in regulatory decisions;
•
Effect in stakeholders’ interaction.
The reflection should also cover how legislation, as well as Agenda - EMA Human Scientific Committees' Working Parties with Patients’ and Consumers’ Organisations (PCWP) and Healthcare Professionals’ Organisations (HCPWP) joint meeting Workshop on social media
Page 2/3
19 September 2016 geographical and cultural uptake of social media need to be factored in. 13:15
Lunch
14:15
3.2
Feedback from the breakout sessions
4. Is social media enabling medicine-related data gathering? Session chair: Peter Arlett, EMA Head of Pharmacovigilance and Epidemiology 15:00
4.1
From Social to Medical: how is digital information being
C. Cattuto (ISI Foundation)
used? 4.2
How could this data be relevant to regulatory decision-
J. Raine (PRAC Chair)
making? 4.3
Recent learnings from the IMI WEBrADR project
16:15
Coffee
16:30
Open discussion to identify areas requiring further attention
P. Tregunno (MHRA)
from regulators, patients and healthcare professionals. 17:00
Take home messages by I. Moulon/ P. Arlett/ M-A. Heine
17:15
End of meeting
Agenda - EMA Human Scientific Committees' Working Parties with Patients’ and Consumers’ Organisations (PCWP) and Healthcare Professionals’ Organisations (HCPWP) joint meeting Workshop on social media
Oct 26, 2016 - (as Web sites for social networking and microblogging) through ... 5. Identify areas requiring further attention from regulators, patients and ...
Jul 7, 2017 - COMMUNITY MARKETING AUTHORISATIONS AND EXTENSIONS. 2.1. Opinions ... Quality. Rapp: E. Werner .... solutions table with EMA and CVMP responses to the recommendations made by the FishMed Plus. Coalition ...
Jun 19, 2017 - and may also vary during the course of the review. ...... ViiV Healthcare UK Limited; Treatment of Human Immunodeficiency Virus ..... adjunctive administration of brivaracetam, Treatment of paediatric patients with partial.
Jun 15, 2016 - Agenda - EMA Human Scientific Committees' Working. Parties with Healthcare Professionals' Organisations. (HCPWP) meeting. 15 June 2016, 08:45hrs to 10:30hrs â meeting room: 3E. Chairs: I. Moulon (EMA) and Gonzalo Calvo (HCPWP). 15 Ju
Feb 9, 2018 - 30 Churchill Place â Canary Wharf â London E14 5EU â United Kingdom. An agency of the European Union ... product information. For information: Summary of opinion. 2.2. Oral explanations and list of outstanding issues. â¢. Product
Oct 23, 2017 - Page 2/61. Table of contents. 1. Introduction. 11. 1.1. Welcome and declarations of interest of members, alternates and experts .......... 11. 1.2. Agenda of the meeting on 23-26 October 2017 . ...... different database to study the ri
17 Jan 2018 - Expert meeting on adeno-associated viral vectors, 06 September 2017, EMA, London. CAT: Martina SchüÃler-Lenz. Scope: report of the meeting that took place on 6 September 2017. Action: for adoption. 7.6.3. Environmental assessment of g
Dec 7, 2016 - publication of clinical data (Policy 0070) and revisions to the guidance to industry â Industry Associations Webinar. 9 December 2016, 10:00 to ...
Sep 19, 2017 - 14:00-14:05. 2. Data integrity â early signal detection. - data patterns/trends in data ... 16:20-17:00. 5. Inspections of Ligand Binding Assays (in.
Nov 7, 2017 - 30 Churchill Place â Canary Wharf â London E14 5EU â United Kingdom. An agency of the European Union. Telephone ...... Visualisation of choline metabolism in malignant neoplasms ..... A paediatric investigation plan (PIP) is a dev
Jan 23, 2018 - Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be
Oct 24, 2017 - Application of Article 8(2) of the Orphan Regulation ..... propoxy)-phenyl]-methanone, EMA/OD/187/14 Herpes simplex type 1 virus containing.
Jun 14, 2016 - 30 Churchill Place â Canary Wharf â London E14 5EU â United Kingdom ... EMA initiatives to support and accelerate early access. 10:00 2.1 ...
6 days ago - EMA/OD/103/14 Donor T lymphocytes depleted ex vivo of host alloreactive T cells using photodynamic treatment, EMA/OD/175/14 Allogeneic ...
o Pilot to test draft model ... Endorsement of Enpr-EMA membership criteria Mark Turner/Irmgard. Eichler ... Endorsement of newly received applications.
Jan 23, 2018 - HCP/patient cross-sectional survey and retrospective chart review Post Authorisation. Safety Study to evaluate the effectiveness of the Patient Alert Card for both IV and SC abatacept in a sample of EU countries. Positive Opinion adopt
Jan 8, 2018 - Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. ... EU referral procedures for safety reasons: urgent EU procedures 13. 2.1. ...... clinical data from st
Nov 3, 2016 - Scope: 'Optimising the development of ATMPs to meet patient needs' ... the CAT would like to discuss with company representatives in person.
Jul 7, 2017 - EMEA/V/C/002526. Rapp: G. J. Schefferlie. For adoption: CVMP assessment report on the targeted. PSUR for the period 11.02.14-31.12.16 ...
Oct 23, 2017 - under Article 107i of Directive 2001/83/EC, based on pharmacovigilance data. Action: For adoption of ..... manufacturing process; and 3) removal of the following missing information: special patient groups. Action: For .... analysis of
Jan 8, 2018 - information (RSI) adopted in July 2017. Action: For adoption of advice to CHMP. 7.2.15. Naltrexone hydrochloride, bupropion hydrochloride - MYSIMBA (CAP) -. EMEA/H/C/003687/MEA 004.4. Applicant: Orexigen Therapeutics Ireland Limited. PR